Options for Delivering Isoniazid-Rifapentine (3HP) for TB Prevention (3HP Options Implementation Trial)

Key facts

Sponsor

University of California, San Francisco

Principal Investigator

Adithya Cattamanchi, MD, M.D

University of California, San Francisco

Intervention

Streamlined weekly DOT visits(other)

Enrollment

1656 enrolled

Eligibility

18-100 years · All sexes

Timeline

2020 – 2025

Study locations (1)

• Mulago Immune Suppression Syndrome (ISS) Clinic, Kampala, Uganda

Collaborators

Makerere University · Johns Hopkins Bloomberg School of Public Health · University of Colorado, Denver · National Heart, Lung, and Blood Institute (NHLBI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Primary genito-urinary tuberculosis

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT05917210
  Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda
  Yale University
• RECRUITINGNCT07312266
  Questioning the Epidemiology of Asymptomatic TB
  Barcelona Institute for Global Health
• RECRUITINGNANCT05842161
  South Africa Smoking Cessation and Engagement in HIV/TB Care Care
  Massachusetts General Hospital
• RECRUITINGPHASE3NCT05575518
  A Pragmatic Trial With Optimized Dose of Rifampicin and Moxifloxacin for the Treatment of Drug Susceptible Pulmonary Tuberculosis
  Stellah Mpagama
• ACTIVE NOT RECRUITINGPHASE4NCT05118490
  Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis Patients
  The Aurum Institute NPC
• RECRUITINGNANCT05342064
  Closing -TB GAPs - for People Living With HIV: TB Guidance for Adaptable Patient-Centered Service
  Baylor College of Medicine

See all trials for Primary genito-urinary tuberculosis →